Currently, several small molecule inhibitors of BTK, such as ibrutinib, acalabrutinib, and zanubrutinib, have been approved for the treatment of certain types of lymphoma that have relapsed and/or have not responded to other therapies.14 Here, BTK is linked to lymphoma.